Anaptysbio ANAB
NASDAQ ANAB
$56.40 -1.06 (-1.84%)
As of: Sep 4, 2026 · 1:26 PM EDT

Anaptysbio (ANAB) Operating Income Growth (3y) (2019 - 2026)

Analysis

Anaptysbio (ANAB) Operating Income Growth (3y) (2019 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 8.36%
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 89.72%
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn 24.14%
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 44.54%
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 44.34%
8 Royalty Pharma 28.44 Bn 27.60 Bn - -18.82%
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 81.27%
10 Anaptysbio 1.62 Bn 1.33 Bn - 7.94%
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 7.94%
Dec 31, 2025 66.02%
Sep 30, 2025 46.92%
Jun 30, 2025 1.99%
Mar 31, 2025 4.63%
Dec 31, 2024 32.29%
Sep 30, 2024 -49.85%
Jun 30, 2024 -322.93%
Mar 31, 2024 -31.97%
Dec 31, 2023 -48.33%
Sep 30, 2023 -15.74%
Jun 30, 2023 -21.04%
Mar 31, 2023 -63.00%
Dec 31, 2022 -5.28%
Sep 30, 2022 4.24%
Jun 30, 2022 -1.41%
Mar 31, 2022 -8.62%
Dec 31, 2021 -16.58%
Sep 30, 2021 26.29%
Jun 30, 2021 66.69%